Medtronic: FDA approves InterStim II System for treatment of overactive bladder, urinary retention

By Lisa Kerner

Charlotte, N.C., July 5 - Medtronic, Inc. said the Food and Drug Administration approved its InterStim II system, which uses sacral nerve stimulation, for the treatment of intractable cases of overactive bladder and urinary retention.

The new system recently received the CE Mark in Europe and is already approved in the United States for the treatment of non-obstructive urinary retention and the symptoms of overactive bladder.

"This new smaller, lighter device - combined with the array of smart design changes to other components of the implantable system - will make InterStim Therapy more attractive to both physicians and patients," Steven W. Siegel, director of Metropolitan Urologic Specialists' Center for Continence Care in St. Paul, Minn., said in a company news release.

Medtronic said the InterStim iCon Patient Programmer offers new programming features, allowing patients to adjust the stimulation amplitude, while the N'Vision Clinician Programmer allows the physician to design and track patients' stimulation programs.

Medtronic is a medical technology company based in Minneapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.